Cowen reissued their buy rating on shares of Aptinyx (NASDAQ:APTX) in a research report report published on Wednesday, AnalystRatings.com reports.
Several other equities analysts have also weighed in on the stock. JPMorgan Chase & Co. assumed coverage on shares of Aptinyx in a research report on Wednesday, October 14th. They set a neutral rating for the company. BMO Capital Markets restated a buy rating and set a $13.00 price objective on shares of Aptinyx in a research report on Friday, August 14th. SunTrust Banks assumed coverage on shares of Aptinyx in a research report on Wednesday, July 1st. They set a buy rating and a $15.00 price objective for the company. SVB Leerink raised their price objective on shares of Aptinyx from $12.00 to $14.00 and gave the company an outperform rating in a research report on Tuesday, October 20th. Finally, William Blair restated a buy rating on shares of Aptinyx in a research report on Thursday, October 1st. Two analysts have rated the stock with a hold rating and six have given a buy rating to the company. Aptinyx currently has an average rating of Buy and a consensus price target of $10.25.
Shares of APTX opened at $3.13 on Wednesday. The firm has a 50-day moving average price of $3.45 and a 200 day moving average price of $3.65. The firm has a market capitalization of $146.75 million, a PE ratio of -2.14 and a beta of 1.21. Aptinyx has a 52-week low of $1.60 and a 52-week high of $6.47.
Hedge funds have recently bought and sold shares of the business. Two Sigma Advisers LP lifted its position in shares of Aptinyx by 5.0% in the second quarter. Two Sigma Advisers LP now owns 105,800 shares of the company’s stock worth $441,000 after purchasing an additional 5,000 shares in the last quarter. UBS Group AG lifted its position in shares of Aptinyx by 2,549.0% in the second quarter. UBS Group AG now owns 7,947 shares of the company’s stock worth $33,000 after purchasing an additional 7,647 shares in the last quarter. Public Employees Retirement System of Ohio purchased a new stake in shares of Aptinyx in the second quarter worth approximately $37,000. Leap Investments LP purchased a new stake in shares of Aptinyx in the second quarter worth approximately $58,000. Finally, American International Group Inc. purchased a new stake in shares of Aptinyx in the second quarter worth approximately $63,000. 59.26% of the stock is owned by institutional investors.
Aptinyx Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. It is developing NYX-2925 that is in Phase II clinical trial for the treatment of painful diabetic peripheral neuropathy, as well as in Phase II exploratory clinical trial for fibromyalgia; and NYX-783, an NMDAr receptor that is in Phase I clinical trial for the treatment of post-traumatic stress disorder.
Further Reading: Death Cross
Receive News & Ratings for Aptinyx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptinyx and related companies with MarketBeat.com's FREE daily email newsletter.